CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated, as plasma sourcing is a key constraint in production. The plasma sourcing market is currently largely balanced with demand. CSL is well positioned, having rationalized its plasma collection centers.
CSL is investing in plasma yield initiatives, leaving it well positioned to take advantage of growth opportunities in the key immunoglobulins market.
Areas of the plasma industry could be replaced by newer therapies, which would leave CSL overinvested in plasma collection and fractionation capacity that will be hard to repurpose.
|
Metric
|
CSL
|
4502
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.09 | 48.22 | 11.55 |
Price/Book Value | 3.91 | 1.20 | 1.35 |
Price/Sales | 3.65 | 1.96 | 1.73 |
Price/Cash Flow | 16.30 | 10.96 | 7.15 |
|
Metric
|
CSL
|
4502
|
SNY
|
|---|---|---|---|
Quick Ratio | 0.88 | 0.54 | 0.49 |
Current Ratio | 2.21 | 1.14 | 0.99 |
Interest Coverage | −8.46 | 0.07 | 8.05 |
|
Metric
|
CSL
|
4502
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 8.38% | 5.53% | 7.96% |
Return on Equity (Normalized) | 17.61% | 11.34% | 14.96% |
Return on Invested Capital (Normalized) | 11.10% | 7.74% | 11.28% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|c@>Zy%q | LOCK|#rT%G | $128B | |||
| Moderna Inc
MRNA
| LOCK|cm#$yqk | LOCK|mk | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xNl&ryS | LOCK|##nq@ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|?P<>Kd | LOCK|T<& | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|k<^Nm$ | LOCK|TK | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|yYV<m^d | LOCK|#$S#< | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|x!?bzC& | LOCK|VS?! | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|<?Jsld | LOCK|>S | $24B | |||
| Incyte Corp
INCY
| LOCK|$Z&v?PX | LOCK|#N | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|j&>@xS | LOCK|>?R | $15B |
United States